Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell

MT newswire2026/10/06 08:59

04:59 AM EDT, 10/06/2026 (MT Newswires) -- Spyre Therapeutics (SYRE) priced an offering of about 4.12 million common shares at $85 each, targeting about $350 million in gross proceeds, the company said late Monday. Underwriters have a 30-day option to purchase up to an additional $52.5 million of shares. Spyre Therapeutics expects the offering to close by Wednesday and intends to use the net proceeds to continue to advance its programs in gastroenterology, rheumatology, and dermatology, among other things, it said. The company's shares were down 2.1% in premarket activity Tuesday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.